Prima BioMed and Fraunhofer Institute in A$5.35m grant for CVac™ ovarian cancer trial

Prima BioMed (ASX: PRR) has shared in a EUR 4.1 million (A$5.35 million) grant with the Fraunhofer Institute of Cell …
more